Dr. Dinorah Morvinski

Dr. Friedmann-Morvinskinew laboratory is engaged in developing novel strategies to attack mainly the cancer stem cell subpopulation in Glioblastoma, which has been linked to radiation and chemotherapy resistance. Dr. Friedmann-Morvinski has identified a novel marker expressed on glioma cells. Here, in collaboration with Prof. Zelig Eshhar, the pioneer of CAR-immunotherapy, the scientific team designed a CAR-T cell targeting this newly identified glioma marker. The ultimate goal is to combine adoptive immune gene therapy and nanotechnology to target glioma stem cells. Using an integrative approach to study brain tumor (glioma)-specific neurobiology and oncobiology, the lab research currently explores the following directions:
• Examining the parallel changes in oncogenesis and the induction of pluripotency
• Elucidating the mechanisms involved in cancer cell plasticity
• Understanding the molecular basis of tumor cell heterogeneity and the contribution of the tumor microenvironment
• Identifying the molecular events involved in gliomagenesis
• Designing novel therapeutic approaches combining adoptive immune gene therapy and nanotechnology

 

Collaborators in the lab’s work include: 
Prof. Zelig Eshhar,  Prof. Dan Peer – TAU, Prof.  Shankar Subramaniam- UCSD
Prof. Mario L Suva- MIT, MGH, Harvard
Prof. David Jones, and Prof. Peter Lichter - German Cancer Research Center (DKFZ)
Rafi Mazor - UCSD

Lab Website: https://dinorah2908.wixsite.com/dfm-lab

Contact info:
Dinorah Friedmann-Morvinski PhD
Faculty of Life sciences
dino@post.tau.ac.il

 

Tel Aviv University, P.O. Box 39040, Tel Aviv 6997801, Israel
UI/UX Basch_Interactive